Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
Crossref DOI link: https://doi.org/10.1007/s12325-015-0234-0
Published Online: 2015-08-18
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Iijima, Hiroaki
Kifuji, Takayuki
Maruyama, Nobuko
Inagaki, Nobuya
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation